Gene expression profiling of breast cancer to select women for adjuvant chemotherapy
BlueCross BlueShield Association
Record ID 32010000212
English
Authors' objectives:
This Assessment examines whether, compared to conventional risk assessment tools, the use of gene expression profiling improves outcomes when used to decide whether risk of recurrence is low enough to forego adjuvant chemotherapy for early stage breast cancer.
Details
Project Status:
Completed
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Adult
- Chemotherapy, Adjuvant
- Device Approval
- Female
- Gene Expression Profiling
- Patient Selection
- Risk Factors
- Treatment Outcome
- Breast Neoplasms
- Gene Expression Regulation, Neoplastic
- Neoplasm Recurrence, Local
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
<p>BlueCross BlueShield Association (BCBS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.